Neuland Laboratories Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

July 3, 2026
Posted by: Kunal Singla
Category: News

Neuland Laboratories CMP Rs.19,082. Q1 FY27E revenue Rs.419-482 Cr. PAT estimate Rs.18-23 Cr. 12-month target Rs.22,898-25,379.

Neuland Laboratories Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Neuland Laboratories shares trading at Rs.19,082 against a market capitalisation of Rs.24,354 Cr and a price-to-earnings multiple of 66.9. As a pharmaceuticals and life sciences name on the NSE and BSE, Neuland Laboratories enters the Neuland Laboratories Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

This Neuland Laboratories Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.301 Cr revenue and Rs.14 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.

Get Free Investment Predictions and Neuland Laboratories Research at Univest

Table of Contents

About Neuland Laboratories

Neuland Laboratories (NSE: NEULANDLAB) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings. Ahead of the Neuland Laboratories Q1 Results FY27 print, the company’s Q4 FY26 base shows revenue of Rs.789 Cr and net profit of Rs.213 Cr, forming the base against which the Neuland Laboratories Q1 Results FY27 estimates in this article are built. This Neuland Laboratories Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Neuland Laboratories Q1 FY27 Estimates

Metric	Q1 FY27E (Range)	Q1 FY26 Actual	YoY Growth
Revenue (Rs. Cr)	419-482	301	+50.0%
Net Profit / PAT (Rs. Cr)	18-23	14	+50.0%
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.22,898-25,379

Univest, a SEBI-Registered Investment Advisor, Tracks Neuland Laboratories Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. CDMO Pipeline Visibility

Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Neuland Laboratories’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Neuland Laboratories share price target or faces renewed pressure.

2. New Product Approvals

New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Neuland Laboratories’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Neuland Laboratories share price target or faces renewed pressure.

3. Capacity Scale-Up

Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Neuland Laboratories’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Neuland Laboratories share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Neuland Laboratories’s live price and Q1 FY27 result updates.

Key Risks to the Neuland Laboratories Q1 Results FY27 Outlook

Pricing pressure in key export markets, particularly the US generics segment.
Regulatory or plant compliance issues affecting supply continuity.
R&D and capacity expansion costs weighing on near-term profitability.

Q4 FY26 Performance Context for the Neuland Laboratories Q1 Results FY27 Print

Neuland Laboratories closed Q4 FY26 with revenue of Rs.789 Cr and net profit of Rs.213 Cr, a year-on-year revenue change of +134.9% and PAT change of +664.7%. This base underpins the Neuland Laboratories Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Neuland Laboratories Q1 Results FY27 commentary once reported.

Technical Analysis Ahead of Neuland Laboratories Q1 Results FY27

Neuland Laboratories shares last traded at Rs.19,082. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Neuland Laboratories Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Neuland Laboratories Q1 Results FY27 trailing-growth framework points to a range of Rs.19,988-21,515 for Neuland Laboratories, contingent on the Neuland Laboratories Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Neuland Laboratories Q1 Results FY27 view for Neuland Laboratories works out to Rs.22,898-25,379, built on the same trailing revenue growth trend and current valuation multiple. Tracking with a constructive bias is how Univest research categorises the stock heading into Neuland Laboratories Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Neuland Laboratories Q1 Results FY27 analysis would put Neuland Laboratories in a Rs.26,142-29,577 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Neuland Laboratories Q1 Results FY27 Print

Revenue and PAT versus the Neuland Laboratories Q1 Results FY27 estimate range in this preview.
Management commentary on FY27 growth guidance and margin trajectory relevant to the Neuland Laboratories Q1 Results FY27 narrative.
Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility
Pricing pressure in key export markets, particularly the US generics segment

Conclusion on Neuland Laboratories Q1 Results FY27

Neuland Laboratories enters the Q1 FY27 results season trading at Rs.19,082, with the 12-month Uniresearch target range of Rs.22,898-25,379 reflecting a tracking with a constructive bias stance. Investors tracking the Neuland Laboratories Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Neuland Laboratories Q1 Results FY27

When are Neuland Laboratories Q1 FY27 results expected?

Ans. Neuland Laboratories’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Neuland Laboratories Q1 FY27 revenue estimate?

Ans. The Uniresearch trailing-growth estimate for Neuland Laboratories’s Q1 FY27 revenue is Rs.419-482 Cr, based on the Q1 FY26 base of Rs.301 Cr.

What is the Neuland Laboratories share price target?

Ans. The 12-month Uniresearch estimate for Neuland Laboratories share price target is Rs.22,898-25,379, based on trailing growth and current valuation multiples.

Is Neuland Laboratories a good buy before Q1 FY27 results?

Ans. Neuland Laboratories is tracking with a constructive bias heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Neuland Laboratories’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.

Where can I track Neuland Laboratories share price live?

Ans. Neuland Laboratories share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.